Johnson & Johnson to acquire Proteologix in $850m deal to enhance immunology portfolio
Johnson & Johnson (NYSE: JNJ) has entered into a definitive agreement to acquire Proteologix, Inc., a leading biotechnology company specializing in the development of bispecific antibodies for immune-mediated diseases. The deal, valued at $850 million in cash, also includes potential additional milestone payments. This acquisition marks a significant expansion of Johnson & Johnson’s immunology portfolio, […]